Evaluation of Gemtuzumab Ozogamicin and Anthracycline Dosing for Favorable Risk Acute Myeloid Leukemia
European Journal of Haematology · 2025
DOI: 10.1111/ejh.14354 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Joseph F Mort und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Medicine, The University of Virginia, Charlottesville, Virginia, USA. Hauptthemen laut MEDLINE: Gemtuzumab, Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Gemtuzumab ozogamicin (GO) is a CD33‐targeting antibody‐drug conjugate approved for the treatment of CD33‐positive de novo and relapsed and refractory acute myeloid leukemia (AML). Subset analyses have demonstrated improved clinical outcomes in patients with favorable‐risk disease. It is unclear whether the addition of GO to cytarabine and anthracycline chemotherapy (7+3) improves clinical outcomes compared with other conventional regimens for AML. We evaluated the real‐world experience with GO added to 7+3 chemotherapy for patients with favorable risk AML. This retrospective analysis included 174 patients with de novo favorable risk AML undergoing induction chemotherapy between 2010 and 2020. The primary outcome was overall survival (OS) and secondary outcomes included rates of remission, measurable residual disease (MRD), and toxicity. Eighteen patients received GO, 37 received a high‐dose (HD) anthracycline, and 119 received an intermediate‐dose anthracycline. Composite complete remission was achieved in 162 patients (93.1%). Among the 54 patients who were assessed for MRD at remission, 66.7% were undetectable. An improvement in OS was seen for patients who received GO and those treated with HD anthracycline, which was better explained by differences in patient performance status and comorbidities. Patients who received GO did not show increased toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology and Oncology, Department of Medicine, The University of Virginia, Charlottesville, Virginia, USA.
- Department of Public Health Sciences, The University of Virginia, Charlottesville, Virginia, USA.
- Division of Hematology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.
- Division of Hematology and Oncology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
- Section of Hematology and Oncology, Department of Internal Medicine, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, USA.
- Department of Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
ORCID-Profile: Joseph F Mort, Joshua F Zeidner, Vu H Duong, Daniel R Reed, Bhagirathbhai Dholaria, Thomas W LeBlanc, Firas El Chaer
Zitieren
APA
Mort, J. F., Brighton, D., DiBenedetto, S., Wells, L., Clark, S. M., Reid, J., Patel, I., Jackson, C., Yelvington, B., Miller, R., Perciavalle, M., Walsh, K., Wolfe, H., Locke, S. C., Zeidner, J. F., Duong, V. H., Reed, D. R., Dholaria, B., LeBlanc, T. W., …, & El Chaer, F. (2025). Evaluation of Gemtuzumab Ozogamicin and Anthracycline Dosing for Favorable Risk Acute Myeloid Leukemia. European Journal of Haematology. https://doi.org/10.1111/ejh.14354
Vancouver
Mort JF, Brighton D, DiBenedetto S, Wells L, Clark SM, Reid J, et al. Evaluation of Gemtuzumab Ozogamicin and Anthracycline Dosing for Favorable Risk Acute Myeloid Leukemia. European Journal of Haematology. 2025. doi:10.1111/ejh.14354
BibTeX
@article{Mort2025,
author = {Mort, Joseph F and Brighton, David and DiBenedetto, Samantha and Wells, Leah and Clark, Stephen M and Reid, Justin and Patel, Imari and Jackson, Clayton and Yelvington, Bradley and Miller, Ryan and Perciavalle, Matthew and Walsh, Katherine and Wolfe, Heather and Locke, Susan C and Zeidner, Joshua F and Duong, Vu H and Reed, Daniel R and Dholaria, Bhagirathbhai and LeBlanc, Thomas W and Keng, Michael and Horton, Bethany and El Chaer, Firas},
title = {Evaluation of Gemtuzumab Ozogamicin and Anthracycline Dosing for Favorable Risk Acute Myeloid Leukemia},
journal = {European Journal of Haematology},
year = {2025},
doi = {10.1111/ejh.14354}
}
EUVIMED